Get informed when a big investor buys or sells
+ FollowOvervalued by 26.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $62.34 Billion |
|---|---|
| Enterprise Value | $65.16 Billion |
| Annual dividend | $0.85 |
| Dividend yield | 0.49% |
| Earnings per Share | $3.93 |
| Beta | 0.2 |
| Outstanding Shares | 381,195,514 |
| P/E Ratio | 25.67 |
|---|---|
| PEG | 18.53 |
| Price to Sales | 3.79 |
| Price to Book Ratio | 5.06 |
| Enterprise Value to Revenue | 4.22 |
| Enterprise Value to EBIT | 14.74 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.31 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $1.36M▼ 27.26% |
| Investors Holding | 70% |
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized p...